Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2530 participants.
Also called NCT05142722
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,530 participants
- Sponsor
- Registry
-
NCT05142722
-
- Main results
- Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
- Other papers using this trial's data
- Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, Czechia, Denmark, Georgia, Japan, Netherlands, Poland
- Registry status
- Completed
Technical summary
Registry record NCT05142722. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-15 (actual); primary completion 2024-09-26 (actual). Results posted on 2025-09-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
- Acronym
- BROADWAY
- Condition
- Dyslipidemias
- Condition
- High Cholesterol
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Obicetrapib
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct05142722- Content hash
83c7f38118c138e61de89940647a23a9cfdffab3e9d43c665df0a8f86645ad00